Further studies are warranted to associate our findings in peripheral immune cell subsets with tumor samples from larger patient cohorts with comparison with other types of therapies in randomized phase II/III trials studying anti–LAG-3 combination therapies to reveal the detailed mechanism of action of this drug. This evidence concerns the gene LAG3 and neoplasm.